SCHEDULE: Intracoastal Capital Discloses 8.1% Stake in Processa Pharma
Beneficial Ownership Disclosure
Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported beneficial ownership of 8.1% of Processa Pharmaceuticals, Inc. common stock.
Summary
- Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G Amendment No. 2.
- The Reporting Persons beneficially own 200,000 shares of Processa Pharmaceuticals, Inc. common stock.
- This ownership represents approximately 8.1% of the common stock outstanding.
- The shares are issuable upon the exercise of a warrant held by Intracoastal Capital LLC (the "Intracoastal Warrant").
- The calculation of the percentage is based on 2,265,768 shares of common stock outstanding as of December 12, 2025, as reported by the Issuer, plus the 200,000 shares from the Intracoastal Warrant.
- The Reporting Persons share both voting and dispositive power over the 200,000 shares.
- The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure, as Schedule 13G filings are standard regulatory requirements for reporting significant passive ownership stakes and do not inherently convey positive or negative operational news.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors acquiring significant stakes. For a pharmaceutical company like Processa Pharmaceuticals, a substantial ownership stake by an investment entity can signal investor confidence or a strategic position, though this filing explicitly states the securities were not acquired for the purpose of changing or influencing control.
Stakeholder Impact
- Shareholders: Increased transparency regarding significant ownership stakes, potentially signaling investor interest in Processa Pharmaceuticals, Inc.
Key Dates
| Date | Description |
|---|---|
| 12/12/2025 | Date Processa Pharmaceuticals, Inc. reported 2,265,768 shares of Common Stock outstanding. |
| 12/31/2025 | Date of the event which required the filing of this statement (beneficial ownership threshold met). |
| 02/13/2026 | Date the Schedule 13G was signed by the reporting persons. |
Keywords
Processa Pharmaceuticals, Intracoastal Capital, Mitchell Kopin, Daniel Asher, beneficial ownership, Schedule 13G, common stock, warrant, pharmaceutical, biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.